Axinn filed two petitions on December 11, 2017 for inter partes review (IPR) of U.S. Patent No. 8,846,100 and U.S. Patent No. 9,173,857 on behalf of KVK-Tech, Inc. and Abhai LLC related to Shire LLC’s Mydayis®, a brand name drug used to treat attention deficit hyperactivity disorder (ADHD) in patients 13 years and older. The petitions challenge claims directed to three-bead amphetamine salt drug formulations and methods of treating ADHD using those formulations. The Axinn team representing KVK-Tech, Inc. and Abhai LLC consists of Jonathan Harris, Chad Landmon, James Evans and Thomas Hedemann.
Axinn Files IPR Petitions Challenging Patents on Shire LLC’s Drug Mydayis®
December 12, 2017